Infection in Renal Transplant Recipients

  • Jay A. Fishman
    Address reprints requests to Jay A. Fishman, MD, Transplant Infectious Disease and Compromised Host Program, Massachusetts General Hospital, 55 Fruit St, GRJ 504, Boston, MA 02114.
    Harvard Medical School, MGH Transplant Center, Transplant Infectious Disease and Compromised Host Program, Infectious Disease Division, Massachusetts General Hospital, Boston, MA.
    Search for articles by this author


      Renal transplant recipients are susceptible to infection by a wide array of pathogens. Impaired inflammatory responses due to immunosuppressive therapies suppress clinical and radiologic findings engendered by microbial invasion. As a result, patients are often minimally symptomatic and evaluation and diagnosis are delayed. Specific microbiologic diagnosis is essential both for the optimization of antimicrobial therapy and to avoid unnecessary drug toxicities. Differential diagnosis is guided by knowledge of organisms commonly involved in infection in immunocompromised hosts and understanding of the limitations of prophylactic strategies. The risk of infection in the organ transplant recipient is determined by the interaction between the individual’s epidemiologic exposures and net state of immunosuppression. Epidemiology includes environmental exposures in the community and hospital, organisms derived from donor tissues and latent infections activated in the host during immune suppression. The net state of immune suppression is determined by the interaction of all factors contributing to infectious risk. Routine antimicrobial prophylaxis is aimed at common infections and unique risk factors in individual patient groups. This includes trimethoprim-sulfamethoxazole (for Pneumocystis, Toxoplasma, most Nocardia and Listeria, common urinary pathogens), perioperative (eg, anti-fungal prophylaxis for pancreas transplants), or antiviral (for herpesviruses in high risk recipients).


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Seminars in Nephrology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Fishman J.A.
        • Rubin R.H.
        Infection in organ-transplant recipients.
        N Engl J Med. 1998; 338: 1741-1751
        • Wilck M.
        • Fishman J.
        The challenges of infection in transplantation: donor-derived infections.
        Curr Opin Organ Transplant. 2005; 10: 301-306
        • Schaffner A.
        Pretransplant evaluation for infections in donors and recipients of solid organs.
        Clin Infect Dis. 2001; 33: S9-S14
        • Delmonico F.L.
        • Snydman D.R.
        Organ donor screening for infectious diseases: review of practice and implications for transplantation.
        Transplantation. 1998; 65: 603-610
        • Delmonico F.L.
        Cadaver donor screening for infectious agents in solid organ transplantation.
        Clin Infect Dis. 2000; 31: 781-786
        • Rosengard B.R.
        • Feng S.
        • Alfrey E.J.
        • et al.
        Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor.
        Am J Transplant. 2002; 2: 701-711
        • Freeman R.B.
        • Giatras I.
        • Falagas M.E.
        • et al.
        Outcome of transplantation of organs procured from bacteremic donors.
        Transplantation. 1999; 68: 1107-1111
        • Kasiske B.L.
        • Ravenscraft M.
        • Ramos E.L.
        • Gaston R.S.
        • Bia M.J.
        • Danovitch G.M.
        • Ad Hoc Clinical Practice Guidelines Subcommittee of the Patient Care and Education Committee of the American Society of Transplant Physicians
        The evaluation of living renal transplant donors: clinical practice guidelines.
        J Am Soc Nephrol. 1996; 7: 2288-2313
        • Kasiske B.L.
        • Ramos E.L.
        • Gaston R.S.
        • et al.
        • Patient Care and Education Committee of the American Society of Transplant Physicians
        The evaluation of renal transplant candidates: clinical practice guidelines.
        J Am Soc Nephrol. 1995; 6: 1-34
        • Fischer S.A.
        • Graham M.B.
        • Kuehnert M.J.
        • et al.
        Transmission of lymphocytic choriomeningitis virus by organ transplantation.
        N Engl J Med. 2006; 354: 2235-2249
        • Avery R.K.
        Infections and immunizations in organ transplant recipients: a preventive approach.
        Cleve Clin J Med. 1994; 61: 386-392
        • Avery R.K.
        Prophylactic strategies before solid-organ transplantation.
        Curr Opin Infect Dis. 2004; 17: 353-356
        • Singh N.
        • Paterson D.L.
        Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management.
        Clin Infect Dis. 1998; 27: 1266-1277
        • Fishman J.A.
        • Rubin R.H.
        Solid organ transplantation in HIV-infected individuals: obstacles and opportunities.
        Transplant Proc. 2001; 33: 1310-1314
        • Razonable R.R.
        • Paya C.V.
        Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections.
        Herpes. 2003; 10: 60-65
        • Humar A.
        • Gillingham K.
        • Payne W.D.
        • Sutherland D.E.
        • Matas A.J.
        Increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus disease.
        Transplantation. 2000; 70: 310-313
        • Preiksaitis J.K.
        • Brennan D.C.
        • Fishman J.
        • Allen U.
        Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report.
        Am J Transplant. 2005; 5 ([erratum appears in Am J Transplant 2005;5:635]): 218-227
        • Prosch S.
        • Wuttke R.
        • Kruger D.H.
        • Volk H.D.
        NF-kappaB—a potential therapeutic target for inhibition of human cytomegalovirus (re)activation?.
        Biol Chem. 2002; 383: 1601-1609
        • Fietze E.
        • Prosch S.
        • Reinke P.
        • et al.
        Cytomegalovirus infection in transplant recipients.
        Transplantation. 1994; 58: 675-680
        • Sester M.
        • Sester U.
        • Gartner B.
        • et al.
        Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation.
        Transplantation. 2001; 71: 1287-1294
        • Sester M.
        • Sester U.
        • Gartner B.C.
        • Girndt M.
        • Meyerhans A.
        • Kohler H.
        Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection.
        J Am Soc Nephrol. 2002; 13: 2577-2584
        • Lowance D.
        • Neumayer H.H.
        • Legendre C.M.
        • et al.
        • International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group
        Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation.
        N Engl J Med. 1999; 340: 1462-1470
        • Kalil A.C.
        • Levitsky J.
        • Lyden E.
        • Stoner J.
        • Freifeld A.G.
        Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.
        Ann Intern Med. 2005; 143: 870-880
        • Humar A.
        • Mazzulli T.
        • Moussa G.
        • et al.
        Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R− transplant recipients.
        Am J Transplant. 2005; 5: 1065-1070
        • Caliendo A.M.
        • Yen-Lieberman B.
        • Baptista J.
        • et al.
        Comparison of molecular tests for detection and quantification of cell-associated cytomegalovirus DNA.
        J Clin Microbiol. 2003; 41: 3509-3513
        • Humar A.
        • Kumar D.
        • Boivin G.
        • Caliendo A.M.
        Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease.
        J Infect Dis. 2002; 186: 829-833
        • Funch D.P.
        • Walker A.M.
        • Schneider G.
        • Ziyadeh N.J.
        • Pescovitz M.D.
        Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients.
        Am J Transplant. 2005; 5: 2894-2900
        • Sagedal S.
        • Hartmann A.
        • Nordal K.P.
        • et al.
        Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival.
        Kidney Int. 2004; 66: 329-337
        • Harris N.L.
        • Ferry J.A.
        • Swerdlow S.H.
        Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop.
        Semin Diagn Pathol. 1997; 14: 8-14
        • Opelz G.
        • Henderson R.
        Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients.
        Lancet. 1993; 342: 1514-1516
        • Paya C.V.
        • Fung J.J.
        • Nalesnik M.A.
        • et al.
        Epstein-Barr virus-induced posttransplant lymphoproliferative disorders.
        Transplantation. 1999; 68: 1517-1525
        • Preiksaitis J.K.
        • Keay S.
        Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients.
        Clin Infect Dis. 2001; 33: S38-S46
        • Green M.
        • Michaels M.G.
        • Webber S.A.
        • Rowe D.
        • Reyes J.
        The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients.
        Pediatr Transplant. 1999; 3: 271-281
        • Mylonakis E.
        • Goes N.
        • Rubin R.H.
        • Cosimi A.B.
        • Colvin R.B.
        • Fishman J.A.
        BK virus in solid organ transplant recipients: an emerging syndrome.
        Transplantation. 2001; 72: 1587-1592
        • Hirsch H.H.
        • Suthanthiran M.
        The natural history, risk factors and outcomes of polyomavirus BK-associated nephropathy after renal transplantation.
        Nat Clin Pract Nephrol. 2006; 2: 240-241
        • Drachenberg C.B.
        • Hirsch H.H.
        • Ramos E.
        • Papadimitriou J.C.
        Polyomavirus disease in renal transplantation: review of pathological findings and diagnostic methods.
        Hum Pathol. 2005; 36: 1245-1255
        • Hirsch H.H.
        • Brennan D.C.
        • Drachenberg C.B.
        • et al.
        Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations.
        Transplantation. 2005; 79: 1277-1286
        • Hirsch H.H.
        Polyomavirus BK nephropathy: a (re-)emerging complication in renal transplantation.
        Am J Transplant. 2002; 2: 25-30
        • Hirsch H.H.
        • Knowles W.
        • Dickenmann M.
        • et al.
        Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients.
        N Engl J Med. 2002; 347: 488-496
        • Randhawa P.
        • Vats A.
        • Shapiro R.
        Monitoring for polyomavirus BK And JC in urine: comparison of quantitative polymerase chain reaction with urine cytology.
        Transplantation. 2005; 79: 984-986
        • Randhawa P.
        • Ho A.
        • Shapiro R.
        • et al.
        Correlates of quantitative measurement of BK polyomavirus (BKV) DNA with clinical course of BKV infection in renal transplant patients.
        J Clin Microbiol. 2004; 42: 1176-1180
        • Nickeleit V.
        • Klimkait T.
        • Binet I.F.
        • et al.
        Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy.
        N Engl J Med. 2000; 342: 1309-1315
        • Vats A.
        • Randhawa P.S.
        • Shapiro R.
        Diagnosis and treatment of BK virus-associated transplant nephropathy.
        Adv Exp Med Biol. 2006; 577: 213-227
        • Trofe J.
        • Hirsch H.H.
        • Ramos E.
        Polyomavirus-associated nephropathy: update of clinical management in kidney transplant patients.
        Transplant Infect Dis. 2006; 8: 76-85
        • Hirsch H.H.
        • Ramos E.
        Retransplantation after polyomavirus-associated nephropathy: just do it?.
        Am J Transplant. 2006; 6: 7-9
        • Fishman J.A.
        Prevention of infection due to Pneumocystis carinii.
        Antimicrob Agents Chemother. 1998; 42: 995-1004
        • Rodriguez M.
        • Fishman J.A.
        Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.
        Clin Microbiol Rev. 2004; 17: 770-782
        • Fishman J.A.
        Prevention of infection caused by Pneumocystis carinii in transplant recipients.
        Clin Infect Dis. 2001; 33: 1397-1405
        • Champion L.
        • Stern M.
        • Israel-Biet D.
        • et al.
        Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients.
        Ann Intern Med. 2006; 144 ([summary for patients in Ann Intern Med. 2006;144:I45]): 505-509